Anti-LRP/LR specific antibodies and shRNAs impede amyloid beta shedding in Alzheimer's disease

Citations Over TimeTop 13% of 2013 papers

Abstract

Alzheimer's disease (AD) is the most prevalent form of dementia. The amyloid beta (Aβ) peptide is the predominant candidate aetiological agent and is generated through the sequential proteolytic cleavage of the Amyloid Precursor Protein (APP) by beta (β) and gamma (γ) secretases. Since the cellular prion protein (PrP(c)) has been shown to regulate Aβ shedding, we investigated whether the cellular receptor for PrP(c), namely the 37 kDa/67 kDa Laminin Receptor (LRP/LR) played a role in Aβ shedding. Here we show that LRP/LR co-localises with the AD relevant proteins APP, β- and γ-secretase, respectively. Antibody blockage and shRNA knock-down of LRP/LR reduces Aβ shedding, due to impediment of β-secretase activity, rather than alteration of APP, β- and γ-secretase levels. These findings indicate that LRP/LR contributes to Aβ shedding and recommend anti-LRP/LR specific antibodies and shRNAs as novel therapeutic tools for AD treatment.

Related Papers

• → Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging.(1994)469 cited
• Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease.(1998)
• → The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43)(1997)106 cited
• Differential effect of agents altering vesicular pH on the generation of amyloid beta-peptide derived from mutant or wild type beta-APP(1994)
• Accumulation of Alzheimer's beta-amyloid peptide in cultured smooth muscle cells is regulated by beta-peptide carrier proteins(1995)